Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Recruiting

• Conditions: Overactive Bladder Syndrome
• Interventions: Drug: Solifenacin Oral Tablet; Drug: Mirabegron 25mg

• Registration Number: NCT05040984
• Lead Sponsor: Far Eastern Memorial Hospital

Brief Summary

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-30
• Study First Submitted: 2021-09-02
• Study First Submitted QC: 2021-09-09
• Study First Posted: 2021-09-10
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-27
• Last Update Posted: 2023-03-29
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

• Women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment

Read More

Exclusion Criteria

• <20 year-old

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
solifenacin	Solifenacin Oral Tablet	-
mirabegron	Mirabegron 25mg	-

Primary Outcome Measures

Name	Time	Method
Predictors of persistence of mirabegron versus solifenacin use	13 years

Trial Locations

Locations (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital; 🇨🇳 Banqiao, New Taipei, Taiwan